Published in Birth Defects Res A Clin Mol Teratol on November 19, 2011
Motherisk update. Is ondansetron safe for use during pregnancy? Can Fam Physician (2012) 1.21
The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel) (2013) 0.92
Maternal age, parity and isolated birth defects: a population-based case-control study in Shenzhen, China. PLoS One (2013) 0.90
The Leading Concerns of American Women with Nausea and Vomiting of Pregnancy Calling Motherisk NVP Helpline. Obstet Gynecol Int (2013) 0.89
Allopurinol Use during Pregnancy - Outcome of 31 Prospectively Ascertained Cases and a Phenotype Possibly Indicative for Teratogenicity. PLoS One (2013) 0.80
Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007. Pharmacoepidemiol Drug Saf (2013) 0.80
Nausea in pregnancy: attitudes among pregnant women and general practitioners on treatment and pregnancy care. Scand J Prim Health Care (2016) 0.79
Treatment of nausea and vomiting during pregnancy -a cross-sectional study among 712 Norwegian women. Eur J Clin Pharmacol (2016) 0.78
EUROmediCAT signal detection: an evaluation of selected congenital anomaly-medication associations. Br J Clin Pharmacol (2016) 0.78
Treatment of nausea in pregnancy: a cross-sectional multinational web-based study of pregnant women and new mothers. BMC Pregnancy Childbirth (2015) 0.77
Nausea and vomiting during pregnancy and neurodevelopmental outcomes in offspring. Paediatr Perinat Epidemiol (2014) 0.75
Nausea and vomiting of pregnancy - What's new? Auton Neurosci (2016) 0.75
Ondansetron and pregnancy: Understanding the data. Obstet Med (2015) 0.75
Headache in pregnancy: an approach to emergency department evaluation and management. West J Emerg Med (2015) 0.75
Antihistamines and birth defects: a systematic review of the literature. Expert Opin Drug Saf (2014) 0.75
Treatment of Nausea and Vomiting in Pregnancy: Factors Associated with ED Revisits. West J Emerg Med (2016) 0.75
Off-label use of ondansetron in pregnancy in Western Australia. Biomed Res Int (2013) 0.75
Doxylamine succinate-pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview. Int J Womens Health (2014) 0.75
Nausea and vomiting in early pregnancy and the risk of neural tube defects: a case-control study. Sci Rep (2015) 0.75
Using latent class cluster analysis to screen high risk clusters of birth defects between 2009 and 2013 in Northwest China. Sci Rep (2017) 0.75
The National Birth Defects Prevention Study. Public Health Rep (2001) 5.50
Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Reprod Toxicol (1996) 4.21
Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol (2003) 3.75
Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med (2010) 3.31
The management of nausea and vomiting of pregnancy. J Obstet Gynaecol Can (2002) 2.05
The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG (2004) 2.04
The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol (2009) 2.03
Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstet Gynecol (2005) 1.88
Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology (2000) 1.78
ACOG (American College of Obstetrics and Gynecology) Practice Bulletin: nausea and vomiting of pregnancy. Obstet Gynecol (2004) 1.64
Over-the-counter medications in pregnancy. Am Fam Physician (2003) 1.58
Orofacial clefts in the National Birth Defects Prevention Study, 1997-2004. Am J Med Genet A (2009) 1.55
Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol (2007) 1.34
Treatment of nausea and vomiting in pregnancy: an updated algorithm. Can Fam Physician (2007) 1.29
Risk factors for cytogenetically normal holoprosencephaly in California: a population-based case-control study. Am J Med Genet (2000) 1.24
On the use of affected controls to address recall bias in case-control studies of birth defects. Teratology (1994) 1.14
Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol (2009) 1.12
First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol (2003) 1.12
Prenatal exposure to salicylates and gastroschisis: a case-control study. Teratology (1997) 1.09
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol (2010) 1.07
The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med (2009) 1.07
Optimal management of nausea and vomiting of pregnancy. Int J Womens Health (2010) 1.07
Prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancy. Am J Obstet Gynecol (2003) 1.04
Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol (2005) 0.99
Nausea and vomiting of pregnancy: endocrine basis and contribution to pregnancy outcome. Obstet Gynecol Surv (2001) 0.97
Nausea during pregnancy and congenital heart defects: a population-based case-control study. Am J Epidemiol (1999) 0.94
Use of omeprazole during pregnancy--no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol (2001) 0.93
Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci (2002) 0.93
Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol (1999) 0.91
Maternal corticosteroid use and hypospadias. J Pediatr (2009) 0.91
The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol (1998) 0.90
The safety of drugs for the treatment of nausea and vomiting of pregnancy. Expert Opin Drug Saf (2007) 0.86
Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol (1998) 0.82
Proton-pump inhibitors and birth defects--some reassurance, but more needed. N Engl J Med (2010) 0.80
H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet (2009) 12.32
Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA (2002) 10.03
Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol (2002) 9.76
Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA (2010) 5.94
Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med (2006) 5.91
Decline in the prevalence of spina bifida and anencephaly by race/ethnicity: 1995-2002. Pediatrics (2005) 4.91
First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med (2007) 4.25
Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol (2011) 4.14
Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med (2007) 3.79
Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol (2003) 3.75
Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol (2011) 3.42
Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol (2005) 3.37
Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet (2002) 3.35
The contribution of preterm birth to infant mortality rates in the United States. Pediatrics (2006) 3.01
Asthma morbidity after the short-term use of ibuprofen in children. Pediatrics (2002) 2.90
A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics (2003) 2.88
Emerging infections and pregnancy. Emerg Infect Dis (2006) 2.75
Seeking causes: Classifying and evaluating congenital heart defects in etiologic studies. Birth Defects Res A Clin Mol Teratol (2007) 2.69
Recent trends in use of herbal and other natural products. Arch Intern Med (2005) 2.65
Birth outcomes following West Nile Virus infection of pregnant women in the United States: 2003-2004. Pediatrics (2006) 2.53
Prevalence and characteristics of opioid use in the US adult population. Pain (2008) 2.49
Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med (2007) 2.43
Identification of phthalates in medications and dietary supplement formulations in the United States and Canada. Environ Health Perspect (2011) 2.40
Assisted reproductive technology and major structural birth defects in the United States. Hum Reprod (2008) 2.38
Maternal occupational exposure to organic solvents during early pregnancy and risks of neural tube defects and orofacial clefts. Occup Environ Med (2012) 2.35
Maternal obesity and risk for birth defects. Pediatrics (2003) 2.33
Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol (2012) 2.14
What obstetrician-gynecologists should know about Ebola: a perspective from the Centers for Disease Control and Prevention. Obstet Gynecol (2014) 2.04
Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. Am J Epidemiol (2008) 1.97
Alcohol consumption by women before and during pregnancy. Matern Child Health J (2008) 1.94
Control selection and participation in an ongoing, population-based, case-control study of birth defects: the National Birth Defects Prevention Study. Am J Epidemiol (2009) 1.93
Lack of periconceptional vitamins or supplements that contain folic acid and diabetes mellitus-associated birth defects. Am J Obstet Gynecol (2011) 1.89
Trends and predictors of folic acid awareness and periconceptional use in pregnant women. Am J Obstet Gynecol (2005) 1.78
Induced Abortions and the Risk of Preeclampsia Among Nulliparous Women. Am J Epidemiol (2015) 1.76
Periconceptional use of opioids and the risk of neural tube defects. Obstet Gynecol (2013) 1.76
Reduced risks of neural tube defects and orofacial clefts with higher diet quality. Arch Pediatr Adolesc Med (2011) 1.73
Maternal nutrient intakes and risk of orofacial clefts. Epidemiology (2006) 1.70
Maternal exposure to methotrexate and birth defects: a population-based study. Am J Med Genet A (2014) 1.70
Neural tube defects and maternal folate intake among pregnancies conceived after folic acid fortification in the United States. Am J Epidemiol (2008) 1.69
2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol (2011) 1.69
Association between pregnancy intention and reproductive-health related behaviors before and after pregnancy recognition, National Birth Defects Prevention Study, 1997-2002. Matern Child Health J (2009) 1.68
Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ (2015) 1.68
Maternal smoking and environmental tobacco smoke exposure and the risk of orofacial clefts. Epidemiology (2007) 1.67
Prescription medication borrowing and sharing among women of reproductive age. J Womens Health (Larchmt) (2008) 1.64
A population-based study of craniosynostosis in metropolitan Atlanta, 1989-2003. Am J Med Genet A (2008) 1.63
Maternal asthma medication use and the risk of gastroschisis. Am J Epidemiol (2008) 1.62
Are children born after assisted reproductive technology at increased risk for adverse health outcomes? Obstet Gynecol (2004) 1.61
Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol (2012) 1.56
Update: Interim Guidelines for Health Care Providers Caring for Pregnant Women and Women of Reproductive Age with Possible Zika Virus Exposure - United States, 2016. MMWR Morb Mortal Wkly Rep (2016) 1.56
Orofacial clefts in the National Birth Defects Prevention Study, 1997-2004. Am J Med Genet A (2009) 1.55
Use of selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot. Epidemiology (2014) 1.54
Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recomm Rep (2004) 1.52
Erythromycin use during pregnancy in relation to pyloric stenosis. Am J Obstet Gynecol (2002) 1.50
Maternal smoking and congenital heart defects. Pediatrics (2008) 1.49
Health concerns of women and infants in times of natural disasters: lessons learned from Hurricane Katrina. Matern Child Health J (2007) 1.48
Medications as a potential source of exposure to phthalates in the U.S. population. Environ Health Perspect (2008) 1.45
Maternal hypertension, medication use, and hypospadias in the National Birth Defects Prevention Study. Obstet Gynecol (2014) 1.45
Medication use among children <12 years of age in the United States: results from the Slone Survey. Pediatrics (2009) 1.41
Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007. Paediatr Perinat Epidemiol (2013) 1.40
Maternal butalbital use and selected defects in the national birth defects prevention study. Headache (2013) 1.39
Using bayesian models to assess the effects of under-reporting of cannabis use on the association with birth defects, national birth defects prevention study, 1997-2005. Paediatr Perinat Epidemiol (2014) 1.39
Association between prepregnancy body mass index and congenital heart defects. Am J Obstet Gynecol (2009) 1.38
Cough and cold medication use by US children, 1999-2006: results from the slone survey. Pediatrics (2008) 1.36
Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension (2009) 1.35
Is there a direct effect of pre-eclampsia on cerebral palsy not through preterm birth? Paediatr Perinat Epidemiol (2010) 1.35
Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry (2009) 1.34
Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol (2007) 1.34